Last updated: September 4, 2026
Sodium iodide I-131 is a mature, low-growth radiopharmaceutical used primarily for hyperthyroidism and differentiated thyroid cancer. Its commercial economics are driven by radioactive decay, reactor and processing capacity, hospital distribution networks, reimbursement, and production reliability rather than by conventional small-molecule patent exclusivity. Public companies generally do not disclose standalone I-131 revenue, so financial analysis must rely on supplier scale, radiopharmaceutical segment results, procedure volumes, and supply conditions.
What is sodium iodide I-131 used for?
Sodium iodide I-131 is an oral radioactive iodine product. The thyroid concentrates iodine, allowing I-131 emissions to destroy thyroid tissue or thyroid cancer cells.
| Clinical use |
Commercial role |
Typical administration |
| Hyperthyroidism |
Established treatment competing with antithyroid drugs and surgery |
Oral capsule or solution |
| Differentiated thyroid cancer |
Ablation or treatment of residual thyroid tissue and metastatic disease |
Oral capsule or solution |
| Thyroid diagnostic imaging |
Limited relative to I-123 because of radiation burden and imaging characteristics |
Oral administration |
I-131 has an approximately 8.02-day physical half-life and emits beta radiation for therapeutic effect and gamma radiation that permits imaging [1]. The short half-life restricts inventory duration and creates a delivery requirement that does not apply to conventional oral drugs.
The product is generally supplied as sodium iodide I-131 in capsules or oral solution, with activity measured in millicuries or megabecquerels. Product specifications, labeling, radiation safety controls, and dosage calibration are more important to purchasing decisions than brand differentiation.
How large is the sodium iodide I-131 market?
No authoritative public source reports a global standalone market value for sodium iodide I-131. Commercial estimates are difficult because suppliers report revenue by broader categories such as nuclear medicine, therapeutic radiopharmaceuticals, or diagnostic imaging.
The addressable market is best understood as a procedure-driven niche within the broader radiopharmaceutical market. Demand is supported by:
- Continued incidence of thyroid cancer.
- Large installed populations with hyperthyroidism.
- Use of radioactive iodine in post-surgical thyroid cancer management.
- Expansion of nuclear medicine departments.
- Increased interest in therapeutic radiopharmaceutical manufacturing and distribution.
The market is constrained by:
- The availability of alternatives such as surgery, antithyroid drugs, and external-beam radiation in selected cases.
- Radiation-protection requirements.
- Short shelf life.
- Limited ability to hold inventory.
- Localized supply chains.
- Declining use of I-131 for some diagnostic applications.
Thyroid cancer is among the most frequently diagnosed endocrine malignancies, although incidence trends differ by country and are affected by diagnostic practices. The American Cancer Society estimates that the United States will record tens of thousands of new thyroid cancer cases annually, supporting a persistent treatment base for radioactive iodine [2]. Hyperthyroidism, particularly Graves' disease and toxic nodular disease, provides a broader but more variable demand pool.
What is the financial trajectory for sodium iodide I-131?
The financial trajectory is mature and defensive rather than high-growth. Unit pricing can be stable in normal supply conditions, but supplier margins are exposed to production interruptions, transport costs, isotope availability, and low-volume hospital ordering patterns.
Revenue drivers
Revenue is generated through a combination of:
- Activity-based pricing, usually linked to the amount of radioactivity supplied.
- Product presentations, including capsules and oral solutions.
- Hospital and nuclear medicine center contracts.
- Distribution and delivery services.
- Supply agreements with radiopharmacies and healthcare systems.
The same nominal dose can have different economic value depending on delivery distance, activity calibration time, packaging, and whether the supplier provides direct hospital delivery or uses a radiopharmacy intermediary.
Margin structure
I-131 production is subject to fixed and semi-fixed costs. These include reactor irradiation, chemical processing, quality control, packaging, radioactive-material compliance, specialized transport, and facility licensing. The marginal cost of an additional unit can be relatively low when production and delivery networks are operating efficiently, but the cost of maintaining regulated infrastructure is substantial.
The short half-life creates an unusual inventory profile. Unsold product loses value continuously, so suppliers must match production and distribution closely to scheduled treatments. Hospitals also prefer reliable delivery over large inventories.
Public financial disclosure
Curium, Cardinal Health, Jubilant Radiopharma, and other suppliers participate in nuclear medicine markets, but public filings generally do not isolate sodium iodide I-131 revenue. Cardinal Health reports broader pharmaceutical and nuclear medicine activities, while Curium and Jubilant operate across multiple isotopes and radiopharmaceutical products [3, 4]. Standalone I-131 revenue, gross margin, and operating profit are therefore not publicly verifiable.
The most defensible financial conclusion is that I-131 is a recurring, established product with modest volume growth and limited pricing power. Revenue expansion is more likely to come from population growth, treatment adoption, geographic expansion, and supply reliability than from premium pricing.
Which companies supply sodium iodide I-131?
The supply chain includes isotope producers, radiopharmaceutical manufacturers, nuclear pharmacies, specialty distributors, and hospitals.
Major commercial participants
| Company or organization |
Relevant role |
| Curium |
Global nuclear medicine manufacturer and distributor with therapeutic radioisotope capabilities |
| Cardinal Health |
U.S. pharmaceutical and nuclear medicine distribution platform |
| Jubilant Radiopharma |
Radiopharmaceutical manufacturing, nuclear pharmacy, and distribution |
| NorthStar Medical Radioisotopes |
U.S. radioisotope production and technology development |
| NTP Radioisotopes |
South African isotope production and radiopharmaceutical supply |
| IRE |
Belgian radioisotope producer and radiopharmaceutical supplier |
| ANSTO |
Australian nuclear medicine and radioisotope producer |
| Regional nuclear pharmacies |
Local preparation, dispensing, and hospital delivery |
The supplier landscape varies by jurisdiction. A manufacturer may produce or package I-131 while a separate nuclear pharmacy handles dispensing and delivery. In the United States, hospital access may depend more on local radiopharmacy coverage than on national brand recognition.
What FDA regulatory status applies to sodium iodide I-131?
Sodium iodide I-131 is an established FDA-regulated radiopharmaceutical. FDA-approved labeling covers oral dosage forms and therapeutic indications involving hyperthyroidism and thyroid cancer.
FDA regulation focuses on:
- Identity and radionuclide purity.
- Activity assay and calibration.
- Chemical and radiochemical purity.
- Sterility or microbiological controls, where applicable.
- Packaging and radiation shielding.
- Dosage accuracy.
- Facility controls and radioactive-material handling.
- Pharmacological and radiation-safety labeling.
Radiopharmaceuticals are subject to FDA drug requirements as well as Nuclear Regulatory Commission or Agreement State controls governing radioactive materials. In hospitals, administration also depends on licensed nuclear medicine personnel and radiation-safety infrastructure [5, 6].
What is the Orange Book status of sodium iodide I-131?
The Orange Book is relevant for FDA-approved drug products, but the commercial significance of Orange Book listing is limited for this mature product.
Sodium iodide I-131 products may appear under multiple manufacturers, dosage forms, and National Drug Code presentations. The product is generally supplied as a nonproprietary radiopharmaceutical rather than a branded, patent-protected franchise. Orange Book status should therefore be reviewed at the specific product and applicant level, because capsule and oral-solution products may have different entries.
The key business conclusion is that Orange Book-listed patents are not the principal barrier to competition. Regulatory compliance, radioactive-material licensing, production capacity, transportation, hospital qualification, and delivery timing are more significant barriers.
What patents protect sodium iodide I-131?
No single composition-of-matter patent is expected to provide durable exclusivity for sodium iodide I-131 itself. Sodium iodide is an established chemical compound, and I-131 is a radioactive isotope with long-standing medical use.
Potential intellectual-property protection can instead arise from:
- Manufacturing or purification processes.
- Packaging and shielding systems.
- Activity-calibration technologies.
- Automated dispensing equipment.
- Combination products.
- Dosage or treatment protocols.
- Radioisotope production methods.
- Proprietary delivery or imaging systems.
These rights generally protect a process, device, or method rather than the active ingredient itself. Patent coverage must be assessed separately by jurisdiction and product presentation.
How strong is the patent estate?
The patent estate is weak as a barrier to ordinary sodium iodide I-131 competition. The product has:
- No meaningful new-molecule exclusivity.
- Long-established clinical use.
- Multiple potential suppliers.
- Limited formulation differentiation.
- High non-patent operating barriers.
A supplier with patented production technology may have an advantage in cost, isotope access, or reliability, but that protection does not necessarily prevent competitors from selling conventional sodium iodide I-131.
When does sodium iodide I-131 lose exclusivity?
Sodium iodide I-131 does not have a single, commercially decisive loss-of-exclusivity date comparable to a branded small-molecule drug.
The relevant exclusivity periods are usually:
- Any product-specific FDA exclusivity associated with a particular application.
- Patent terms covering a manufacturing process, formulation, or device.
- Local regulatory exclusivity in non-U.S. markets.
- Contractual supply rights.
- Facility or production capacity advantages.
For the underlying active ingredient and established indication, effective market exclusivity has already expired. Generic or multisource competition is therefore structurally available, subject to product approvals and radioactive-material requirements.
Are there Paragraph IV challenges or patent lawsuits?
Paragraph IV litigation is not a central feature of the sodium iodide I-131 market. Such litigation would require a listed patent connected to a specific FDA-approved product and a generic applicant seeking approval before patent expiration.
The market is more likely to experience:
- Product shortages.
- Manufacturing deviations.
- Regulatory inspections.
- Supply-contract disputes.
- Facility licensing issues.
- Transport interruptions.
- Quality or labeling changes.
Publicly visible patent litigation involving the core sodium iodide I-131 product is limited compared with major branded drugs. Patent risk is more relevant to proprietary isotope-production systems, automated dispensing platforms, and next-generation radiopharmaceutical technologies.
What formulation patents protect sodium iodide I-131?
Conventional capsules and oral solutions have limited formulation differentiation. Relevant protection could cover:
- Capsule materials compatible with radioactive contents.
- Solution stability.
- Radioiodine containment.
- Shielded packaging.
- Unit-dose dispensing.
- Calibration and dose-delivery systems.
These features may improve safety and workflow but are unlikely to create broad product exclusivity. In practice, regulatory approval, validated production, and distribution capability matter more than formulation patents.
What generic entry risks exist?
Generic entry risk is high in principle but moderate in practical execution.
A potential competitor must establish:
- A compliant radionuclide source.
- Licensed radioactive-material facilities.
- Validated synthesis or formulation processes.
- Dose calibration and assay capability.
- Qualified packaging and transport.
- Hospital and nuclear pharmacy distribution.
- FDA or local regulatory approval.
- Reliable production scheduling.
These requirements reduce the likelihood that a conventional pharmaceutical generic manufacturer will enter simply because the active ingredient is old. Competition is more likely to come from existing nuclear medicine companies, regional radiopharmacies, or vertically integrated isotope suppliers.
Generic launch scenarios
| Scenario |
Likely market effect |
| New regional supplier |
Local price pressure and improved delivery redundancy |
| Large nuclear medicine company expands capacity |
Lower shortage risk and stronger contracting competition |
| Hospital develops in-house capability |
Limited impact because of licensing and infrastructure costs |
| Supplier outage |
Temporary price increases and order reallocation |
| New thyroid treatment alternative |
Gradual erosion in selected indications |
What manufacturing and IP barriers affect the market?
Manufacturing barriers are stronger than patent barriers.
Reactor and isotope supply
I-131 is produced through nuclear fission or neutron irradiation processes, depending on the production system. Supply depends on reactor schedules, target processing, radioactive-waste management, and downstream purification.
Logistics
The 8-day half-life limits shipping windows. Delayed delivery can reduce usable activity and force rescheduling. Air transport restrictions, national security controls, customs procedures, and radioactive-material rules can affect international supply.
Facility qualification
Manufacturers must operate specialized facilities with radiation shielding, contamination controls, validated analytical testing, and trained personnel. This creates high entry costs even when the drug substance itself is not patent protected.
Manufacturing IP
Proprietary production or separation technology can provide an economic advantage. The strongest IP positions are likely to concern isotope-generation platforms, automated processing, and dose-management systems rather than conventional sodium iodide formulation.
How does sodium iodide I-131 compare with competing thyroid treatments?
| Treatment |
Main advantages |
Main limitations |
| Sodium iodide I-131 |
Established, outpatient use in many cases, effective thyroid ablation |
Radiation precautions, delayed clinical effect, contraindications in pregnancy |
| Antithyroid drugs |
Non-radioactive and reversible |
Relapse, adverse effects, long-term monitoring |
| Thyroidectomy |
Immediate removal of thyroid tissue |
Surgery, anesthesia, lifelong hormone replacement |
| I-123 imaging |
Lower radiation burden for imaging |
Diagnostic only and not a substitute for I-131 therapy |
| External-beam radiation |
Option for selected cancer cases |
Limited use and greater treatment complexity |
I-131 remains economically competitive because it combines established efficacy with comparatively straightforward administration. Surgery and chronic drug therapy compete more directly in hyperthyroidism. In thyroid cancer, treatment decisions depend on tumor risk, residual disease, metastases, prior surgery, and clinical guidelines.
What regulatory and commercial risks could change the financial outlook?
The principal risks are operational and clinical.
Supply interruption
A reactor outage or processing failure can affect multiple markets simultaneously. Because inventory cannot be held for long periods, customers have limited protection against disruption.
Alternative radiopharmaceuticals
The broader radiopharmaceutical sector is moving toward targeted alpha and beta therapies for oncology. These products may attract manufacturing capacity, capital, and regulatory attention. They are not direct substitutes for most thyroid uses, but they can compete for radioisotope infrastructure and specialized labor.
Treatment-pattern changes
Guideline changes, increased use of surgery, or greater use of antithyroid medicines could reduce I-131 volumes in hyperthyroidism. Conversely, increased thyroid cancer treatment and improved access to nuclear medicine could support demand.
Reimbursement
Payment rates vary by country and payer. Hospitals may prioritize suppliers that provide dependable delivery and compliant documentation even when product prices are similar.
Geographic coverage
North America and Europe have relatively developed nuclear medicine infrastructure. Emerging markets may have unmet demand but face constraints in reactor access, licensing, radiation safety, trained staff, and transport networks. Expansion into those markets requires local regulatory and logistics investment.
What is the investment outlook for sodium iodide I-131?
Sodium iodide I-131 is unlikely to be a standalone high-growth investment thesis. Its value is greater as part of a broader nuclear medicine platform.
The most attractive commercial positions are likely to involve:
- Integrated isotope production and radiopharmaceutical manufacturing.
- National or regional delivery networks.
- Multi-isotope portfolios.
- Long-term hospital contracts.
- Proprietary production technology.
- High-reliability supply in shortage-prone markets.
A company dependent on I-131 alone faces limited differentiation and mature demand. A supplier that uses I-131 as an anchor product while expanding into therapeutic isotopes may achieve better growth and operating leverage.
Key Takeaways
- Sodium iodide I-131 is a mature therapeutic radiopharmaceutical used mainly for hyperthyroidism and differentiated thyroid cancer.
- Public companies do not generally disclose standalone I-131 revenue, so exact market size and product-level financial forecasts are not independently verifiable.
- Demand is recurring but likely low-growth, with expansion tied to thyroid cancer treatment, hyperthyroidism prevalence, and nuclear medicine access.
- The main competitive barriers are isotope supply, licensed manufacturing, dose calibration, logistics, and hospital distribution.
- Composition-of-matter patent protection is not a meaningful barrier for conventional sodium iodide I-131.
- Paragraph IV litigation and Orange Book patent disputes are less important than manufacturing, shortage, and regulatory risks.
- The strongest commercial opportunities are in integrated nuclear medicine platforms rather than standalone I-131 products.
- Financial performance is likely to be stable in normal conditions but vulnerable to reactor outages, transport restrictions, and production failures.
FAQs
Is sodium iodide I-131 a generic drug?
It is an established nonproprietary radiopharmaceutical supplied by multiple manufacturers. Product approval remains necessary because radioactive-material handling, quality control, labeling, and dosage calibration are regulated.
Is sodium iodide I-131 profitable for manufacturers?
It can provide recurring revenue, but profitability depends on production scale, reactor access, delivery density, contract terms, and the ability to minimize decay-related waste.
Can hospitals manufacture sodium iodide I-131 themselves?
Most hospitals do not manufacture the product. They generally purchase it from licensed radiopharmaceutical suppliers or nuclear pharmacies because production requires specialized facilities and regulatory approvals.
Does I-131 compete with lutetium-177 radiopharmaceuticals?
The products are not direct clinical substitutes. I-131 is concentrated in thyroid treatment, while lutetium-177 products are used in targeted therapies for selected cancers. They can compete indirectly for isotope infrastructure, radiopharmaceutical manufacturing capacity, and specialized personnel.
What is the biggest risk to I-131 availability?
The largest risk is a disruption in isotope production or processing combined with the short half-life of I-131. Unlike conventional drugs, suppliers and hospitals cannot maintain large long-term inventories.
References
- International Atomic Energy Agency. (2023). Nuclear medicine resources and radioisotope data. IAEA.
- American Cancer Society. (2024). Key statistics for thyroid cancer.
- Cardinal Health. (2024). Annual report 2024. Cardinal Health, Inc.
- Curium. (2024). Products and services. Curium Pharma.
- U.S. Food and Drug Administration. (2024). Drugs@FDA and approved drug labeling for sodium iodide I-131 products. FDA.
- U.S. Nuclear Regulatory Commission. (2024). Medical use of radioactive material. NRC.
